Omeros Corporation
Organization details
- Legal name
- Omeros Corporation
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Washington
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- OMER
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001285819
- EIN
- 91-1663741
Board of directors
-
Arnold C. Hanish · DirectorSince 2023
-
Diana T. Perkinson · DirectorSince 2023
-
Gregory A. Demopulos M.D. · Director · Chairman, CEO & PresidentSince 2024
-
Joseph L. Schocken · DirectorSince 2026
-
Leroy E. Md Hood Ph.D. · DirectorSince 2023
-
Peter A. Demopulos M.D. · DirectorSince 2023
-
Rajiv Shah · DirectorSince 2023
-
Thomas F. Bumol · DirectorSince 2023
-
Thomas J. Cable · DirectorSince 2023
Chief executives
Board connections
1 of this board's directors also sit on 1 other board. 1 is in the same sector.
-
Decoy Therapeutics Inc. Same sectorvia Arnold C. Hanish
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $3,037,180
- 14 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23, 2026 | Borges David J. Officer (VP, Finance & CAO) | Option exercise | +10,000 | $15.58 | $155,800 |
| Sep 23, 2026 | Borges David J. Officer (VP, Finance & CAO) | Open-market sale | −10,000 | $20.95 | $209,500 |
| Sep 22, 2026 | Borges David J. Officer (VP, Finance & CAO) | Option exercise | +5,000 | $3.93 | $19,650 |
| Sep 22, 2026 | Borges David J. Officer (VP, Finance & CAO) | Option exercise | +5,000 | $2.94 | $14,700 |
| Sep 22, 2026 | Borges David J. Officer (VP, Finance & CAO) | Open-market sale | −10,000 | $20.95 | $209,500 |
| Aug 31, 2026 | Cancelmo Peter B Officer (VP, General Counsel) | Option exercise | +25,000 | $2.94 | $73,500 |
| Aug 31, 2026 | Cancelmo Peter B Officer (VP, General Counsel) | Open-market sale | −25,000 | $18.54 | $463,500 |
| Aug 28, 2026 | Cancelmo Peter B Officer (VP, General Counsel) | Option exercise | +25,000 | $2.94 | $73,500 |
| Aug 28, 2026 | Cancelmo Peter B Officer (VP, General Counsel) | Open-market sale | −25,000 | $18.65 | $466,250 |
| Aug 27, 2026 | Arnold C. Hanish Director | Option exercise | +2,500 | $15.81 | $39,525 |
| Aug 27, 2026 | Arnold C. Hanish Director | Option exercise | +7,500 | $14.66 | $109,950 |
| Aug 27, 2026 | Arnold C. Hanish Director | Open-market sale | −5,000 | $18.88 | $94,400 |
| Aug 27, 2026 | Arnold C. Hanish Director | Open-market sale | −5,000 | $19.02 | $95,100 |
| Aug 26, 2026 | Arnold C. Hanish Director | Option exercise | +5,000 | $15.81 | $79,050 |
| Aug 26, 2026 | Arnold C. Hanish Director | Open-market sale | −5,000 | $18.53 | $92,650 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Omeros Corporation
Who is the CEO of Omeros Corporation?
Gregory A. Demopulos M.D. is Omeros Corporation's Chairman, CEO & President.
How many directors are on Omeros Corporation's board?
Omeros Corporation's board has 9 directors: Arnold C. Hanish, Diana T. Perkinson, Gregory A. Demopulos M.D., Joseph L. Schocken, Leroy E. Md Hood Ph.D., Peter A. Demopulos M.D., Rajiv Shah, Thomas F. Bumol and Thomas J. Cable.
Are Omeros Corporation insiders buying or selling shares?
Over the last 12 months, Omeros Corporation insiders made no open-market purchases and sold $3.0 million of shares in 14 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="omeros-corporation"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.